Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
Software Description Platform License Developer .NET Bio Language-neutral toolkit built using the Microsoft 4.0 .NET Framework to help developers, researchers, and scientists .NET Framework: Apache: Collaborative project AMPHORA: Metagenomics analysis software Linux: GPL: Jonathan Eisen: Anduril: Component-based workflow framework for data analysis
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO -- First Phase III Data on Obinutuzumab (GA101) in one of the Most Commonly Diagnosed Blood Cancers -- -- Early ...
Genentech will also have the option to select additional targets in return for an option exercise fee. Price Action: PIRS shares are up 49.3% at $2.76 on the last check Tuesday.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Aviv Regev (born 11 July 1971) [3] is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. [4] She is a core member (on leave) at the Broad Institute of MIT and Harvard and professor (on leave) at the Department of Biology of the Massachusetts ...
Biogen was founded in 1978 in Geneva as Biotechnology Geneva by several prominent biologists, including Kenneth Murray from the University of Edinburgh, Phillip Allen Sharp from the Massachusetts Institute of Technology, Walter Gilbert from Harvard University (Gilbert served as CEO during the start-up phase of Biogen), Heinz Schaller from the University of Heidelberg, and Charles Weissmann ...